AAAAAA

   
Results: 1-17 |
Results: 17
A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer
Authors: Figg, WD Dahut, W Duray, P Hamilton, M Tompkins, A Steinberg, SM Jones, E Premkumar, A Linehan, WM Floeter, MK Chen, CC Dixon, S Kohler, DR Kruger, EA Gubish, E Pluda, JM Reed, E
Citation: Wd. Figg et al., A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer, CLIN CANC R, 7(7), 2001, pp. 1888-1893
Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer
Authors: Rudek, MA Figg, WD Dyer, V Dahut, W Turner, ML Steinberg, SM Liewehr, DJ Kohler, DR Pluda, JM Reed, E
Citation: Ma. Rudek et al., Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer, J CL ONCOL, 19(2), 2001, pp. 584-592
Clinical trial designs for cytostatic agents - Reply
Authors: Korn, EL Arbuck, SG Pluda, JM Simon, R Kaplan, RS Christian, MC
Citation: El. Korn et al., Clinical trial designs for cytostatic agents - Reply, J CL ONCOL, 19(12), 2001, pp. 3154-3155
Clinical trial designs for cytostatic agents: Are new approaches needed?
Authors: Korn, EL Arbuck, SG Pluda, JM Simon, R Kaplan, RS Christian, MC
Citation: El. Korn et al., Clinical trial designs for cytostatic agents: Are new approaches needed?, J CL ONCOL, 19(1), 2001, pp. 265-272
Reversible sideroblastic anemia associated with the tetracycline analogue COL-3
Authors: Rudek, MA Horne, M Figg, WD Dahut, W Dyer, V Pluda, JM Reed, E
Citation: Ma. Rudek et al., Reversible sideroblastic anemia associated with the tetracycline analogue COL-3, AM J HEMAT, 67(1), 2001, pp. 51-53
Approaches to preclinical screening of antiangiogenic agents
Authors: Kruger, EA Duray, PH Price, DK Pluda, JM Figg, WD
Citation: Ea. Kruger et al., Approaches to preclinical screening of antiangiogenic agents, SEMIN ONCOL, 28(6), 2001, pp. 570-576
Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck
Authors: Tseng, JE Glisson, BS Khuri, FR Shin, DM Myers, JN El-Naggar, AK Roach, JS Ginsberg, LE Thall, PF Wang, XM Teddy, S Lawhorn, KN Zentgraf, RE Steinhaus, GD Pluda, JM Abbruzzese, JL Hong, WK Herbst, RS
Citation: Je. Tseng et al., Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck, CANCER, 92(9), 2001, pp. 2364-2373
Drug-induced lupus associated with COL-3 - Report of 3 cases
Authors: Ghate, JV Turner, ML Rudek, MA Figg, WD Dahut, W Dyer, V Pluda, JM Reed, E
Citation: Jv. Ghate et al., Drug-induced lupus associated with COL-3 - Report of 3 cases, ARCH DERMAT, 137(4), 2001, pp. 471-474
Current clinical trials administering the antiangiogenesis agent SU5416
Authors: Via, LE Gore-Langton, RE Pluda, JM
Citation: Le. Via et al., Current clinical trials administering the antiangiogenesis agent SU5416, ONCOLOGY-NY, 14(9), 2000, pp. 1312
Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas
Authors: Fine, HA Figg, WD Jaeckle, K Wen, PY Kyritsis, AP Loeffler, JS Levin, VA Black, PM Kaplan, R Pluda, JM Yung, WKA
Citation: Ha. Fine et al., Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas, J CL ONCOL, 18(4), 2000, pp. 708-715
Phase II evaluation of thalidomide in patients with metastatic breast cancer
Authors: Baidas, SM Winer, EP Fleming, GF Harris, L Pluda, JM Crawford, JG Yamauchi, H Isaacs, C Hanfelt, J Tefft, M Flockhart, D Johnson, MD Hawkins, MJ Lippman, ME Hayes, DF
Citation: Sm. Baidas et al., Phase II evaluation of thalidomide in patients with metastatic breast cancer, J CL ONCOL, 18(14), 2000, pp. 2710-2717
Activity of thalidomide in AIDS-related Kaposis's sarcoma
Authors: Little, RF Wyvill, KM Pluda, JM Welles, L Marshall, V Figg, WD Newcomb, FM Tosato, G Feigal, E Steinberg, SM Whitby, D Goedert, JJ Yarchoan, R
Citation: Rf. Little et al., Activity of thalidomide in AIDS-related Kaposis's sarcoma, J CL ONCOL, 18(13), 2000, pp. 2593-2602
High-performance liquid chromatography with mass spectrometry detection for quantitating COL-3, a chemically modified tetracycline, in human plasma
Authors: Rudek, MA March, CL Bauer, KS Pluda, JM Figg, WD
Citation: Ma. Rudek et al., High-performance liquid chromatography with mass spectrometry detection for quantitating COL-3, a chemically modified tetracycline, in human plasma, J PHARM B, 22(6), 2000, pp. 1003-1014
A pharmacokinetically guided phase II study of carboxyamido-triazole in androgen-independent prostate cancer
Authors: Bauer, KS Figg, WD Hamilton, JM Jones, EC Premkumar, A Steinberg, SM Dyer, V Linehan, WM Pluda, JM Reed, E
Citation: Ks. Bauer et al., A pharmacokinetically guided phase II study of carboxyamido-triazole in androgen-independent prostate cancer, CLIN CANC R, 5(9), 1999, pp. 2324-2329
O-6-benzylguanine: A clinical trial establishing the biochemical modulatory dose in tumor tissue for alkyltransferase-directrd DNA repair
Authors: Spiro, TP Gerson, SL Liu, LL Majka, S Haaga, J Hoppel, CL Ingalls, ST Pluda, JM Willson, JKV
Citation: Tp. Spiro et al., O-6-benzylguanine: A clinical trial establishing the biochemical modulatory dose in tumor tissue for alkyltransferase-directrd DNA repair, CANCER RES, 59(10), 1999, pp. 2402-2410
Pentosan polysulfate - A polysaccharide that inhibits angiogenesis by binding growth factors
Authors: Figg, WD Pluda, JM Sartor, O
Citation: Wd. Figg et al., Pentosan polysulfate - A polysaccharide that inhibits angiogenesis by binding growth factors, CANC DRUG, 3, 1999, pp. 371-383
Thalidomide - A prodrug that inhibits angiogenesis
Authors: Figg, WD Reed, E Green, S Pluda, JM
Citation: Wd. Figg et al., Thalidomide - A prodrug that inhibits angiogenesis, CANC DRUG, 3, 1999, pp. 407-422
Risultati: 1-17 |